Retatrutide + Cagrilintide: Scientific Profile
Publicado el · Actualizado el
A research blend combining retatrutide (a GIP/GLP-1/glucagon triagonist) with cagrilintide (an amylin analog). Two lyophilized reference compounds, HPLC purity with COA per batch. Exclusively for research (RUO).
Mechanism of action
This blend combines retatrutide, a triagonist that activates the GIP, GLP-1 and glucagon receptors, with cagrilintide, a long-acting amylin analog. The triagonist component provides incretin and glucagon signaling (associated with energy expenditure); the amylin component provides satiety signals and regulation of gastric emptying. As reference compounds, they are studied together to investigate the interaction of these pathways. Research material; it is not clinical or dosing guidance for humans.
Mechanism summary
Combination of an incretin triagonist (retatrutide: GIP + GLP-1 + glucagon) with an amylin analog (cagrilintide). It adds the activation of three incretin/metabolic receptors to the amylinergic satiety pathway — of interest for investigating the convergence of multiple metabolic pathways in a single experimental design.
Clinical Studies (6)
There is no peer-reviewed literature on Retatrutide + Cagrilintide as a combination. What follows is the literature for each component separately:
- Sobre Retatrutide: LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept (Coskun T, et al. · Cell Metabolism · 2022) PMID 35985340.
- About Cagrilintide: Development of Cagrilintide, a Long-Acting Amylin Analogue (Kruse, et al. · Journal of Medicinal Chemistry · 2021) PMID 34288673.
- Sobre Retatrutide: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff, et al. · New England Journal of Medicine · 2023) PMID 37366315.
- About Cagrilintide: Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: a Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial (Lau, et al. · The Lancet · 2021) PMID 34798060.
- Sobre Retatrutide: Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials (Pasqualotto E, et al. · Metabolism Open · 2024) PMID 39318607.
- About Cagrilintide: Cagrilintide Lowers Bodyweight Through Brain Amylin Receptors 1 and 3 (Carvas, et al. · EBioMedicine · 2025) PMID 40609154.
Warnings
Retatrutide + Cagrilintide is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- Exclusively for research (RUO). Not suitable for diagnosis or for research in human beings outside a regulated framework.
- Blend of two compounds: no single CAS/formula; see the datasheets for each component.
Technical data
- Compound type
- blend
- Storage
- -20 °C liofilizado; 2-8 °C reconstituido
- Shelf life (lyophilized)
- 24-36 months lyophilized at -20°C
- Shelf life (reconstituted)
- 4-6 weeks reconstituted at 2-8°C
- Light-sensitive
- Sí
Available for research
Retatrutide + Cagrilintide is available as a research reagent (RUO):
Frequently asked questions about Retatrutide + Cagrilintide
What is Retatrutide + Cagrilintide?
A research blend combining retatrutide (a GIP/GLP-1/glucagon triagonist) with cagrilintide (an amylin analog). Two lyophilized reference compounds, HPLC purity with COA per batch.
What is the mechanism of action of Retatrutide + Cagrilintide?
Combination of an incretin triagonist (retatrutide: GIP + GLP-1 + glucagon) with an amylin analog (cagrilintide). It adds the activation of three incretin/metabolic receptors to the amylinergic satiety pathway — of interest for investigating the convergence of multiple metabolic pathways in a single experimental design.
What is Retatrutide + Cagrilintide researched for?
In preclinical research, Retatrutide + Cagrilintide is studied mainly in: Research on combined tri-agonism + amylin; Studies of energy expenditure and satiety; Models of energy metabolism. Material exclusively for scientific research.
How is Retatrutide + Cagrilintide stored?
Condiciones de conservación: -20 °C liofilizado; 2-8 °C reconstituido; estabilidad liofilizado: 24-36 meses liofilizado a -20°C; una vez reconstituido: 4-6 semanas reconstituido a 2-8°C; protéjase de la luz.
What administration routes are studied for Retatrutide + Cagrilintide?
In the research models the following are described: Subcutaneous. Use is exclusively for scientific research.
What precautions should be considered with Retatrutide + Cagrilintide?
Retatrutide + Cagrilintide is material exclusively for research. Exclusively for research (RUO). Not suitable for diagnosis or for research in human beings outside of a regulated framework. Blend of two compounds: no unique CAS/formula; see the data sheets of each component.